Rachit Khandelwal, Pediatrics BMT fellow at Medanta The Medicity, Gurgaon, posted on X:
“Four weeks prior Exposure to broad-spectrum antibiotics Piptaz, imipenam, Meropenem (P-I-M) with CD19 CAR-T therapy is linked to reduced survival in hematologic malignancies.
Gut microbiome diversity plays a crucial role in CAR-T outcomes.”
